Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial potential of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results